Living donor liver transplantation for patients with advanced hepatocellular carcinoma

J. Michael Cullen, Paola Vargas, Nicolas Goldaracena

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Liver transplantation (LT) is the treatment of choice for patients with hepatocellular carcinoma (HCC) and underlying liver disease. Given the organ scarcity, LT for patients with HCC have been restricted to those patients associated with the highest survivals. However, many patients with extended criteria HCC can still benefit from LT, but due to deceased organ shortage, they are not offered that opportunity. Living donor liver transplantation (LDLT) emerged as a successful strategy to overcome organ shortage around the world and as LDLT experience grows, this technique might offer the opportunity to expand the indications of LT to patients with advanced HCC. Therefore, since LDLT is not competing for deceased donor organs, many patients with extended criteria HCC who could still benefit from transplantation may have access to this treatment option. In this review, we will discuss the role of LDLT for patients with advanced-stage HCC and how LDLT allows for safe expansion of HCC transplant criteria.

Original languageEnglish (US)
Article number76
JournalHepatoma Research
StatePublished - 2020
Externally publishedYes


  • clinical outcomes
  • hepatocellular carcinoma
  • liver transplantation
  • Living donor liver transplantation
  • transplant oncology

ASJC Scopus subject areas

  • Hepatology
  • Oncology


Dive into the research topics of 'Living donor liver transplantation for patients with advanced hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this